Composition: Each uncoated vaginal tablet contains Nystatin USP 100,000 IU.
Brand: Nygen–V
Usage: Local treatment of vaginal yeast infection (vulvovaginal candidiasis).
Category: Antifungal Drugs
Therapeutic category: Antifungal / Gynecological anti-infective
SKU: Nystatin Vaginal Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Nystatin Vaginal Tablets USP 100 is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Manufacturer: Healthy Life Pharma Pvt. Ltd. (certification to be verified)
Exporter: Healthy Inc (export credentials to be verified)
Nystatin is a polyene antifungal used locally to treat susceptible Candida infections of the vagina. Nygen–V is specified as an uncoated vaginal tablet containing 100,000 IU Nystatin USP. It is intended for vaginal use only, not for swallowing. A separately listed Nystatin USP 500,000 IU uncoated tablet is a distinct product and must not be represented as the same vaginal dosage form without label confirmation.
Manufacturing and third-party supply enquiries can be directed to Healthy Life Pharma Pvt. Ltd.; actual manufacturing licenses, GMP certification and availability require verification.
| Product | Nystatin Vaginal Tablets / Nygen–V |
|---|---|
| Active ingredient | Nystatin USP |
| Confirmed vaginal strength | 100,000 IU per tablet |
| Dosage form | Uncoated vaginal tablet |
| Route | Intravaginal use only |
| Class | Polyene antifungal |
| CAS | 1400-61-9 |
| Additional listed product | Nystatin Tablets USP 500,000 IU, uncoated; route and indications must be confirmed from its own approved label |
| Pack, shelf life, storage | As stated on the approved finished-product label |
Vaginal tablets require suitable disintegration and local drug release. Nystatin potency and stability must be protected by validated processing and packaging controls. Specific claims about humidity-controlled suites, tablet shape, foaming excipients, applicators and packaging cannot be confirmed without manufacturing records.
Relevant quality controls include identification, microbiological potency expressed in IU, uniformity, appropriate disintegration or release tests, microbiological quality and stability. Acceptance criteria must follow the applicable approved monograph and product specifications; arbitrary dissolution limits should not be claimed.
Nystatin binds to ergosterol in fungal cell membranes, disrupting membrane integrity. Vaginal nystatin is used for susceptible vulvovaginal candidiasis. It is not an antibacterial medicine and is not a substitute for assessment of recurrent, complicated or persistent symptoms. Routine prophylaxis during antibiotic treatment should not be claimed without a specific clinical indication.
Product registration, country-specific labeling, CTD/ACTD dossier availability, Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, Certificate of Analysis, manufacturing licenses and GMP certificates should be confirmed with the supplier before commercial use or tender submission. Packaging configuration and shipping terms are subject to quotation.
Q: Is Nygen–V taken by mouth?
A: No. The 100,000 IU vaginal tablet is intended only for vaginal insertion.
Q: Is the 500,000 IU uncoated tablet the same product?
A: No. The supplied information lists it separately and does not establish a vaginal route for that strength.
Q: Can it be used during pregnancy?
A: Vaginal nystatin has limited systemic absorption, but pregnancy treatment should follow a clinician's advice and locally approved guidance; do not assume every formulation is appropriate.
Q: Is an applicator included?
A: Applicator inclusion depends on the verified commercial pack.
Use only according to the approved product label and the prescribing clinician's instructions. A 100,000 IU vaginal tablet is commonly used intravaginally once daily for a prescribed course, but treatment duration and instructions vary by market and patient. Wash hands before and after insertion. Follow the supplied leaflet for use of any applicator. Do not swallow.
Possible adverse effects include local irritation, burning, itching or hypersensitivity. Seek medical advice if symptoms worsen, persist or recur, or if there is fever, pelvic pain, unusual bleeding or malodorous discharge. Use during pregnancy, menstruation and with barrier contraceptives should follow the specific product leaflet; latex compatibility must not be assumed.
Store in the original packaging under the temperature and moisture conditions stated on the approved label. Keep away from children. Do not recommend refrigeration unless the product-specific label requires it.
Medical information is educational and does not replace an approved prescribing label or clinical advice. Product certifications, pack formats and regulatory status require confirmation before publication.